EGFR and non-small cell lung carcinoma: AXL expression was found to be a poor prognostic marker for OS and disease‐free survival after complete resection of early‐stage NSCLC.23 In advanced NSCLC, PFS for EGFR‐TKI treatment tended to be shorter in patients with AXL expression scores of 3+ than in those with scores of 0 to 2+, although the difference was not statistically significant.